Chapter 76 Left Atrial Appendage Closure: Indication and Technique
|
|
- Brice Goodman
- 5 years ago
- Views:
Transcription
1 Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population between 65 and 75 years of age. The prevalence increases to 8% in those aged more than 80 years 1. Stroke risk in patients with nonvalvular AF (NVAF) is around 3% 5% per year. Overall, AF accounts for up to 30% of stroke in patients over 80 years of age 2. Oral anticoagulation (OAC) is the standard treatment for stroke prevention in patients with NVAF with CHA2DS2-VASc stroke risk score 1 (see ref 3). OAC, including novel OAC (NOAC), are indeed effective in stroke prevention. However, the higher rate of bleeding events reported in several patients is a significant limitation in considering OAC for chronic prophylaxis of stroke 4, 5. Percutaneous left atrial appendage (LAA) occlusion is a new and emerging therapy which provides an alternative to OAC in patients with high stroke risk and contraindication to OAC. RATIONALE The LAA which has been regarded as the most lethal human attachment is the major site in the left atrium (LA) accounting for more than 90% of thrombi formation in patients with NVAF, in contrast to the patients with valvular AF generating only 60% of thrombi in LAA as detected by transoesophageal studies 6. Generally, LAA actively contracts with a distinct pattern of emptying in sinus rhythm, as detected by both transoesophageal echocardiography (TEE) and cardiac magnetic resonance imaging studies. However, in patients with AF, the blood flow velocity in LAA frequently decreases, resulting in stasis and pooling of blood associated with an increased rate of thrombus formation. Hence, the rationale behind occluding LAA is that it can reduce 90% of thrombi formation in patients with NVAF. Currently, LAA closure has been given a class IIB recommendation in recent AHA/ESC guidelines. EVIDENCE Percutaneous left atrial appendage transcatheter occlusion (PLAATO) device was the first approved technology with a self-expanding Nitinol cage covered with a polymeric membrane for percutaneous transcatheter LAA occlusion which was evaluated by two multicentric prospective studies with positive results on 5-year follow-up 7, 8. Later, the feasibility and early experience using the WATCHMAN Left Atrial Appendage System, a self-expanding Nitinol device for percutaneous implantation to seal the LAA, was reported in Importantly, the WATCHMAN is the first and only device that has been evaluated in prospective randomized control trials (RCTs). Most of the evidence for LAA closure as an effective alternative to OAC and NOAC come from two RCTs, the PROTECT AF trial, and the PREVAIL study, and some registry data 9, 10. Details are summarized in Table INDICATIONS Based on the EHRA/European Association of Percutaneous Cardiovascular Interventions expert consensus statement on catheter-based LAAO (THE EP WIRE STUDY), the following patient categories need to assessed to determine the possible indication to LAA closure ( Table 76-2 ). TECHNIQUE The two most commonly used devices for LAA closure are the WATCHMAN and the Amplatzer 641
2 642 SECTION VIII Cardiac Electrophysiology TABLE 76-1 SUMMARY OF REGISTRIES AND RANDOMIZE CONTROLLED TRIALS CONDUCTED IN LEFT ATRIAL APPENDAGE CLOSURE WITH WATCHMAN DEVICE Study (Ref. #) Design PROTECT-AF 9, 11 RCT, N 707: 2 WM; 1 warfarin PREVAIL 10 CAP 12 ASAP 13 RCT, N 407: 2 WM; 1 warfarin Registry, N 460 Registry, N 150 CHADS2, Mean SD Procedural Success (%) Follow-Up Duration pt-yrs (mean 1.8 years) 1588 pt-yrs (mean 2.3 years) 2621 pt-yrs (45 months) Efficacy Events Primary end point: stroke, systemic embolism, CV death: 3.0% WM, 4.9% warfarin per 100 pt-yrs; RR: 0.62; met Primary end point: 3.0% WM, 4.3% warfarin per 100 pt-yrs; RR: 0.71; met Primary end point: 2.3% WM, 3.8% warfarin per 100 pt-yrs; RR: 0.6; met noninferiority and superiority criteria months Stroke, systemic embolism, CV and unexplained death at 18 months: both groups, RR: 1.07; did not meet ( 90 patients, at 18-month follow-up); ischaemic stroke or systemic embolism 7 days; met no inferiority criteria: WM; warfarin Median 0.4 year months All-cause stroke and systemic embolism 2.3%/year; observed ischaemic stroke rate was 77% lower than expected Important Safety Issues with WM Serious pericardial effusion 4.8%, procedural stroke 1.3%, device embolization 0.6%, major bleeding 3.5% (4.1% warfarin), haemorrhagic stroke 0.2% (2.5% warfarin) Major bleeding 4.8% (7.4% warfarin), haemorrhagic stroke 0.6% (3.7% warfarin). 7-day death, ischaemic stroke, systemic embolism and procedure complications met (2.2% WM). Pericardial effusion needing pericardiocentesis, window or surgery 1.9%; procedure stroke 0.4%; device embolization 0.8% Procedural stroke 0%, serious pericardial effusion 2.2% Serious procedure or device-related events 8.7%; pericardial effusion with tamponade 1.3%, device embolism 1.3%, device thrombus 4.0% (with 0.7% causing stroke) Note: ASAP, ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology; CAP, Continued Access Protocol; CHADS2, congestive heart failure history, hypertension history, age 75 years, diabetes mellitus history, stroke or transient ischaemic attack symptoms previously; CV, cardiovascular; PREVAIL, Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation vs. Long-Term Warfarin Therapy; PROTECT-AF, WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation; pt-yrs, patient-years; RCT, randomized controlled trial; RR, risk ratio; WM, WATCHMAN. Source: (Reprinted from JACC: Cardiovascular Interventions, 7/11, Jacqueline Saw, Mathieu Lempereur, Percutaneous Left Atrial Appendage Closure, , with permission from Elsevier by the American College of Cardiology Foundation.)
3 Chapter 76 Left Atrial Appendage Closure: Indication and Technique 643 TABLE 76-2 INDICATIONS TO LEFT ATRIAL APPENDAGE CLOSURE 1. CHA2DS2-VASc 2 but contraindicated to OAC (ICH/ life-threatening bleeding) 2. CHA2DS2-VASc 2 and HAS-BLED 3 3. Embolic events despite OAC (excluding other plausible causes such as carotid artery disease) 4. CHA2DS2-VASc 2 and ESRD (CrCl: ml/min) 5. CHA2DS2-VASc 2 and triple anticoagulant therapy 6. CHA2DS2-VASc 2 and pulmonary vein isolation 7. Alternate to OAC in patients with no increased risk for bleeding 8. Patients 60 years of age in whom the potential side effects and complications of long-term OAC therapy are thought to be more serious than LAAO. Note: CrCl, creatine clearance; ESRD, end-stage renal disease; ICH, intracranial haemorrhage; LAA, left atrial appendage occlusion; OAC, oral anticoagulants. Cardiac Plug (ACP). Here, the technique with ACP is discussed in detail. IMAGING Ideally, a preprocedure TEE should be done to assess the LAA anatomy and feasibility for device occlusion. TEE is done during the procedure to assess LAA anatomy, size of the ostium and size of landing zone which is needed to determine the device size. Ostium of the LAA is measured at the level of the left circumflex artery (LCX) and the left upper pulmonary vein (LUPV). The measurement of landing zone is taken 10 millimetres (mm) inside the ostium perpendicular to the neck of the LAA ( Fig ). The size of the landing zone determines the size of the lobe of ACP being used. ACCESS AND TRANS-SEPTAL PUNCTURE TECHNIQUE The procedure can be done under conscious sedation or general anaesthesia. The site for septal puncture is depicted in Fig The right femoral vein is cannulated using Seldinger technique and 10 French (Fr) sheath is placed. Soft Terumo wire is passed up to the superior vena cava (SVC). 10 Fr sheath is removed and 8 Fr Mullen s sheath with dilator passed over the wire to the SVC. A Brockenbrough septal puncture needle is passed inside the Mullen s sheath and the trans-septal puncture is done under TEE guidance. The important step in this trans-septal procedure which differs from other trans-septal puncture for balloon mitral valvotomy (BMV) is that it is done posterior and inferior to the fossa ovalis under continuous TEE guidance ( Fig ) in order to align the Mullen s sheath with the LAA. The Mullen s sheath is then passed over the puncture needle in the LA and the puncture needle and Mullen s sheath dilator are removed and 6 Fr sizing pigtail catheter is then passed inside the Mullen s sheath into the LA. ANGIOGRAPHY The Mullen s sheath and the pigtail are then guided into the LAA body by anticlockwise torque on the pigtail. Once the pigtail is inside the body of the LAA, angiographic views in right anterior oblique (RAO) 20 degrees and cranial 20 degrees were taken by contrast injections through the Mullen s sheath. LAA ostium measurements and landing zone measurements are done ( Fig ). If required, additional views such as RAO caudal are taken to Transcatheter mitral valve repair (Black X). Left atrial appendage closure (White X), and balloon mitral valvotomy (Blue X) RA = right atrium LA = left atrium IVC = inferior vena cava MV = mitral valve LAA = left atrial appendage RA LA MV LAA Figure TEE showing the LAA and the measurements to be taken (A, ostium of LAA; B, measurement of the landing zone which is 10 mm inside the ostium perpendicular to neck of LAA; C, LUPV; D, LCX). IVC Figure Site for septal puncture for various procedures.
4 644 SECTION VIII Cardiac Electrophysiology Figure The Amplatzer Cardiac Plug and the pacifier principle. Figure TEE-guided trans-septal puncture which is posterior and inferior to the fossa ovalis (A, tenting of the atrial septum; B, Brockenbrough needle). Figure Angiography in right anterior oblique view opacifying the LAA and the measurements to be taken (A, ostium of the LAA; B, distance between the ostium and the landing zone for the device in LAA [10 mm]; C, measurement of the landing zone for the lobe of the device). delineate the LAA anatomy clearly. After angiographic measurements in different views and comparing with TEE measurements, appropriate size of the device is chosen. The device is selected based on the lobe size of ACP and measurement of the landing zone, the lobe size should be 3 6 mm more than the measurements of the landing zone. an Inoue dilator is used to dilate the skin and soft tissues and the interatrial septum. This step has not been described in any of the reviews from other countries and is a novel modification from our experience of doing percutaneous BMV. This step of dilating the soft tissue and interatrial septum allows easy passage of the delivery sheath for device deployment. After dilatation, the delivery sheath is introduced over the super stiff wire to the LUPV. The delivery sheath comes with the device and comes in three sizes 9, 10 and 13 Fr and is selected according to the size of the device. The device is then loaded inside the delivery cable and is flushed under water to remove any air. The device with the delivery cable is then passed inside the delivery sheath and taken to the end of the sheath. The delivery sheath which was resting in the LUPV is then pulled back slightly, which allows it to face the LAA ostium. The device is then pushed out of the delivery sheath till it forms a ball shape, after which the whole system is pushed inside the body of the LAA and continuous monitoring with the help of TEE is done. Once on TEE, it is confirmed that two-third of the lobe is beyond the LCX artery, an anticlockwise torque to the delivery sheath is given and the device is further pushed out till the lobe of ACP is deployed. This anticlockwise torque helps to align the ACP perpendicular to the neck of the LAA. The lobe should attain a shape of a tire before further deployment of the device. Once satisfactory shape and location of the lobe are confirmed on TEE, the disc of the device is deployed by pulling back the delivery sheath and maintaining traction on the delivery cable (Fig. 76-5). TECHNIQUE OF ACP DEVICE IMPLANTATION CHECKLIST BEFORE FINAL RELEASE OF THE DEVICE (CONFIRMED ON TEE) (Fig. 76-6) After angiography, the pigtail is removed and an exchange length super stiff wire is placed in the LUPV and the Mullen s sheath is removed. Then 1. Tire shape of the lobe. 2. Good separation between the lobe and disc. 3. Disc is concave in shape.
5 Chapter 76 Left Atrial Appendage Closure: Indication and Technique Barbs 645 Double Curve Single Curve PTFE 30mm 24mm 33mm 27mm 21mm Preformed curve shapes guide position in LAA Figure WATCHMAN device and delivery sheath. (Reprinted from JACC: Cardiovascular Interventions, 7/11, Jacqueline Saw, Mathieu Lempereur, Percutaneous Left Atrial Appendage Closure, , with permission from Elsevier by the American College of Cardiology Foundation.) Figure Fluoroscopic image showing the final deployed device. 4. Disc seals off the ostium of the LAA. This is confirmed by angiography via injection of contrast through the delivery sheath. It can also be confirmed by colour Doppler on TEE. Jet width up to 3 mm on TEE is accepted across the device. 5. Two-third of the lobe should be inside the LCX artery on TEE. 6. ACP should parallel the LAA neck. 7. If the disc is not sitting at the ostium properly than the delivery cable is pulled slightly and then released, which allows the disc to cover the ostium completely. After confirming all these points, the device is finally released by rotating the delivery cable in anticlockwise manner till the device is finally released. The delivery cable and sheath are taken out and local haemostasis is achieved by local compression at the puncture site. WATCHMAN SIZING AND IMPLANTATION STEPS The sizing for WATCHMAN device is based on the maximum LAA ostium diameter. To be able to accommodate available devices, the LAA ostium diameter should be between 17 and 31 mm (Fig. 76-7). Approximately 9% 25% oversizing from the widest LAA diameter is recommended to ensure adequate device compression and good device hold. This generally corresponds a difference of 2 4 mm. Once the appropriate size device is selected, the prepared delivery system containing the compressed device is introduced into the access sheath. The delivery system is advanced until both the distal marker bands of the delivery system and access sheath are aligned. The device is then unsheathed slowly without forward advancement of the device, while asking the patient to hold breath to allow stable deployment. Once the device is fully unsheathed, the device position is assessed on fluoroscopy and TEE. If the device appears to be too distal, it may be partially recaptured and the access system is withdrawn slightly. The unsheathing process is then reattempted in the new position. On the other hand, if the device seems to be too proximal (or sizing/position is suboptimal), the device may have to be fully recaptured, and a new device and delivery system may have to be used through the existing 14F sheath. Before device release, the four PASS criteria should be met: (1) Position (device distal or at LAA ostium, protrusion of shoulder by 40% to 50% of device depth is acceptable) (2) Anchor (testing stability by retracting the deployment knob and letting go, to assess return to original position) (3) Size (device shoulder compressed 8% 20% of original size on TEE) (4) Seal (assess TEE for any residual flow, must be 5 mm before release) When these criteria are met, the device may be released with a counter-clockwise rotation of the core wire for three to five turns. Final angiography and TEE assessment are then performed. POSTPROCEDURE TREATMENT AND FOLLOW-UP Postprocedure dual antiplatelet is to be continued for 6 months, during which the device completely
6 646 SECTION VIII Cardiac Electrophysiology endothelizes, after which a single antiplatelet is continued indefinitely if no contraindication. Postprocedure TEE is done before discharge to look for early device embolization. Repeat TEE is done at 6 weeks to see for embolization and device endothelization. POSSIBLE COMPLICATIONS 1. Cardiac perforation and pericardial effusion due to trans-septal puncture or due to the device itself in which case it can perforate the LAA. Cardiac perforation up to 7 days is reported due to the device. 2. Pericardial effusion and cardiac tamponade. 3. Device embolization (early and late). 4. Device thrombosis. 5. Stroke/TIA thromboembolism, air embolism. 6. Vascular complications haematoma, bleeding. OUR EXPERIENCE A total of 77 patients aged 65 years with a CHA2DS2- VASc score of 2 and contraindicated to OACs with a HAS-BLED score of 3 were directed for percutaneous LAA closure. Thirty-eight patients were operated in the primary care centre and the rest 39 cases proctored. Gender wise distribution revealed female predominance (52.6%) over male (47.4%) patients eligible for LAA closure. ACP device was used more commonly (73) than WATCHMAN (2). The success rate of the procedure was reported to be around 97.4% with the device being successfully implanted in 75 patients. LAA closure was aborted in two patients on observing that one of the patients presented with LAA anatomy unfavourable for the occlusion and the other had pericardial effusion while attempting to close with a 20 mm ACP. These two cases were part of the initial 15 cases being studied critically, which we believe is a part of the learning curve. Nevertheless, the success rate of the procedure was 100% following these two cases. Post-LAA closure follow-up revealed one case of on-table device embolization, wherein the device was retrieved and repositioned without any complications. All the patients with LAA closure devices are being followed up. REFERENCES 1. Wolf, P. A., Abbott, R. D., & Kannel, W. B. ( 1991 ). Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke, 22, Kannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. ( 1998 ). Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. American Journal of Cardiology, 82, 2N 9N. 3. Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al. ( 2012 ) focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Europace. 14, Glader, E. L., Sjölander M., Eriksson, M., & Lundberg, M. ( 2010 ). Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke, 41, Landmesser, U., & Holmes, D. R., Jr. ( 2012 ). Left atrial appendage closure: A percutaneous transcatheter approach for stroke prevention in atrial fibrillation. European Heart Journal, 33, Blackshear, J. L., & Odell, J. A. ( 1996 ). Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Annals of Thoracic Surgery, 61, Ostermayer, S. H., Reisman, M., Kramer, P. H., Matthews, R. V., Gray, W. A., Block, P. C., et al. ( 2005 ). Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with nonrheumatic atrial fibrillation: Results from the international multi-center feasibility trials. Journal of the American College of Cardiology, 46, Block, P. C., Burstein, S., Casale, P. N., Kramer, P. H., Teirstein, P., Williams, D. O., et al. ( 2009 ). Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovascular Interventions, 2, Holmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., et al. ( 2009 ). Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet, 374, Holmes, D. R., Jr., Kar, S., Price, M. J., Whisenant, B., Sievert, H., Doshi, S. K., et al. ( 2014 ). Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. Journal of the American College of Cardiology, 64, Reddy, V. Y., Doshi, S. K., Sievert, H., Buchbinder, M., Neuzil, P., Huber, K., et al. ( 2013 ). Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation, 127, Reddy, V. Y., Holmes, D., Doshi, S. K., Neuzil, P., & Kar, S. ( 2011 ). Safety of percutaneous left atrial appendage closure: Results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation, 123, Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., et al. ( 2013 ). Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: The ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). Journal of the American College of Cardiology, 61,
Atrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationThessaloniki October 9, Apostolos Tzikas MD, PhD, FESC
7 th IICE Congress Thessaloniki October 9, 2014 Left atrial appendage occlusion with the Amplatzer Amulet: a case report Apostolos Tzikas MD, PhD, FESC Interventional Cardiologist Structural & Congenital
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationSURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES Dr. Marco Barbierato Interventional Cardiology Cardio-Thoraco-Vascular Department
More informationLeft Atrial Appendage Closure Techniques: 2015
Left Atrial Appendage Closure Techniques: 2015 Ramon Quesada, MD, FACP, FACC, FSCAI Medical Director, Interventional Cardiology & Cardiac Research Medical Director, Structural Heart and TAVR Program Baptist
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationCase Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationLeft atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
More informationAbstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationAtrial fibrillation (AF) is a common arrhythmia worldwide
Left Atrial Appendage Closure Under Intracardiac Echocardiographic Guidance: Feasibility and Comparison With Transesophageal Echocardiography Yae Matsuo, MD;* Petr Neuzil, MD, PhD;* Jan Petru, MD; Milan
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationLeft atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationReview Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure with Transeosophageal Echocardiography Guidance
Hindawi Publishing Corporation rombosis Volume 2014, Article ID 832752, 6 pages http://dx.doi.org/10.1155/2014/832752 Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationLeft Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Medicine
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationEurope. Other LAA occlusion devices are in clinical development.
EXPERT REVIEW INTERVENTIONS FOR STRUCTURAL HEART DISEASE Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: rationale, devices in clinical development and insights
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
More informationLeft Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
More informationEndocardial LAA Occlusion: Which Device for Which Patient?
Endocardial LAA Occlusion: Which Device for Which Patient? Roy Beinart, MD Davidai Arrhythmia Center The Leviev Heart Center Sheba Medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center
More informationRole of Imaging in Complex LAA Closure Anatomies
Role of Imaging in Complex LAA Closure Anatomies Sameer Gafoor 1,2 1 Swedish Heart and Vascular: Ming Zhang, Paul Huang, Darryl Wells, Adam Zivin, John Petersen II, Madalena Petrescu, Nimish Muni, Eric
More informationPercutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD
Percutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD Fédération de Cardiologie Hôpital Henri Mondor Créteil Atrial Fibrillation is a major cause of Stroke
More informationIntroduction EP WIRE. ... Keywords
Europace (217), 1 6 doi:1.3/europace/eux254 EP WIRE Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
More informationIs there a role for transcatheter left atrial appendage occlusion?
REVIEW Review Is there a role for transcatheter left atrial appendage occlusion? For patients with atrial fibrillation, successful warfarin therapy is difficult in clinical practice. Thus, it seems logical
More informationLeft atrial appendage closure indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey
Europace (2015) 17, 642 646 doi:10.1093/europace/euv069 EP WIRE Left atrial appendage closure indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey Laurent Pison
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationPercutaneous Epicardial LAA Closure: When Does it Make Sense?
Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia petr.neuzil@gmail.com Disclosures
More informationSafety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
More informationLeft-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
More informationMedical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationFilling the gap: interventional occlusion of incompletely ligated left atrial appendages
Europace (2015) 17, 64 68 doi:10.1093/europace/euu164 CLINICAL RESEARCH Ablation for atrial fibrillation Filling the gap: interventional occlusion of incompletely ligated left atrial appendages Stefano
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationAtrial fibrillation (AF) is the most common
Left Atrial Appendage Closure With the Watchman Device A review of trial results and clinical application. BY JAYANT KHITHA, MD, AND TANVIR K. BAJWA, MD Atrial fibrillation (AF) is the most common arrhythmia
More informationAtrial Fibrillation. Atrial Fibrillation
Atrial Fibrillation Stroke and Blood Thinning Medications What else is available? Srinivas Iyengar, MD, FACC, with Boulder Heart Structural Heart Director, Boulder Community Health 303-622-5849 Atrial
More informationLEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES. Sheetal Chandhok, MD
LEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES Sheetal Chandhok, MD Disclosures Boston Scientific: Speaker (Watchman) Trainer (Watchman) SentreHeart Primary Investigator
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationThe evolving role of left atrial appendage occlusion
ORIGINAL ARTICLE 288 A high-volume single-centre experience The evolving role of left atrial appendage occlusion Raffael A. Ghenzi, Slayman Obeid, Francesco Maisano, Maurizio Taramasso, Ronald Binder,
More informationTrans-septal Catheterization. December 8, Jonathan Tobis, MD Professor of Medicine Interventional Cardiology, UCLA
Trans-septal Catheterization December 8, 2015 Jonathan Tobis, MD Professor of Medicine Interventional Cardiology, UCLA No conflicts of interest for this talk BRK = Brockenbrough needle BRK may be easier
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
More informationNit-Occlud. Coil System for PDA Closure IMPLANTATION POCKET GUIDE. Rx only CV / B. Braun Interventional Systems Inc.
Refer to the Nit-Occlud PDA Instructions for Use for relevant warnings, precautions, complications and contraindications. This device has been designed for single use only. Nit-Occlud Coil System for PDA
More informationClinical Policy Bulletin: Cardiac Devices and Procedures for Occlusion of the Left Atrial Appendage
Close Window Enter CPB Search Term: Go Clinical Policy Bulletin: Cardiac Devices and Procedures for Occlusion of the Left Atrial Appendage Number: 0791 Policy *Please see amendment for Pennsylvania Medicaid
More informationPercutaneous atrial septal defect closure with the Occlutech Figulla Flex ASD Occluder.
Percutaneous atrial septal defect closure with the Occlutech Figulla Flex ASD Occluder. First case with a novel delivery system. Werner Budts, Md, PhD, FESC Congenital and Structural Cardiology University
More information16th ANGIOPLASTY SUMMIT-TCTAP TCTAP 2011 Seoul, Korea, April 27 29, 2011 Left Atrial Appendage Closure State of the Art Horst Sievert, Nina Wunderlich, Maik Gonzaga, Annkathrin Braut, Ilona Hofmann CardioVascular
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
More informationOriginal Article. Introduction. Resumo
Percutaneous : Feasibility, Safety and Effect on Echocardiographic Parameters of Cardiac Function and Anatomy Silvio H. Barberato, Costantino R. F. Costantini, Sergio G. Tarbine, Marcos Denk, Costantino
More informationTrick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 10, NO. 21, 2017 ª 2017 PUBLISHED BY ELSEVIER ON BEHALF OF THE
ª 2017 PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 http://dx.doi.org/10.1016/j.jcin.2017.06.072 STRUCTURAL: ATRIAL INTERVENTION FOCUS Percutaneous
More informationLeft atrial appendage (LAA) closure is now a commercially
Assessing Anatomy for Left Atrial Appendage Closure The roles of TEE and CTA in anatomic assessment and device selection for LAA closure. BY DEE DEE WANG, MD, AND MARVIN H. ENG, MD Left atrial appendage
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 6/2014 Origination: 1/2012 Next Review: 12/2014 Policy Blue Cross and
More informationLive in a Box: Left Atrial Appendage Closure Device
Live in a Box: Left Atrial Appendage Closure Device Fayez Bokhari, MD, FRCPC KFAFH, Jeddah Saudi Arabia Joint Saudi Heart Association/SACIS April 18, 2015 News: Interventional Cardiologists harm patients
More informationEHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion
Europace (2014) 16, 1397 1416 doi:10.1093/europace/euu174 EHRA/EAPCI CONSENSUS STATEMENT EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion Bernhard Meier (EAPCI Chairperson)
More informationDevice-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review
CSE REPORT Iwona Świątkiewicz, Marek Woźnicki, dam Sukiennik, Jacek Kubica Department of Cardiology and Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, ydgoszcz, Poland
More informationDepartment of Neurology, Medical University of Silesia, Hospital No. 7, Professor Leszek Giec Upper Silesian Medical Centre, Katowice, Poland
Original paper Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy Anetta Lasek-Bal
More informationDifferent transseptal puncture for different procedures: Optimization of left atrial catheterization guided by transesophageal echocardiography
Original Article Different transseptal puncture for different procedures: Optimization of left atrial catheterization guided by transesophageal echocardiography Andrea Radinovic 1, Patrizio Mazzone 1,
More informationLAmbre LAA Occluder Updates
LAmbre LAA Occluder Updates 4 th Asia Pacific Congenital & Structural Interventional Symposium 6 th June, 2013 Hong Kong Yat-yin LAM MBBS MRCP FHKCP FHKAM FESC FRCP FACC MD Associate Professor, Prince
More informationLeft Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationTechnology Assessment Report No. 302
Technology Assessment Report No. 302 Economic Analysis of Left Atrial Appendage Closure for patients with atrial fibrillation, high stroke risk, and contraindicated to anticoagulants Last updated May 2018
More informationCommercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
More informationNHS England. Anticoagulation Therapy
NHS England Evidence review: Clinical and Cost- Effectiveness and Adverse Events Associated with Left Atrial Appendage Occlusion in Patients for Whom Anticoagulation Therapy is Contraindicated Anticoagulation
More informationExclusion de l auricule gauche par voie percutanée
Exclusion de l auricule gauche par voie percutanée Jean-Michel Juliard, Dominique Himbert, Pierre Aubry, Eric Brochet, Alec Vahanian Hôpital Bichat, Paris Pas de conflit d intérêt 2012 The Left Atrial
More informationDad needed to get off his blood thinner. His doctor told us about an alternative. It s called
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve
More informationDisclosures 6/16/2015. Preventing Stroke in Atrial Fibrillation Warfarin Intolerance / Non-Compliance
6/16/2015 Data Behind LAA Closure This is Ready for Prime Time! Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia Service The Mount Sinai Hospital vivek.reddy@mountsinai.org
More informationPercutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine
2.02.26 Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine Effective Date August 29, 2014 Subsection Cardiology Original Policy Date July 6,
More informationReference: NHS England 1692
Clinical Commissioning Policy Proposition: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (Adults) Reference: NHS England
More informationWhich System Is better?: Watchman or Cardiac Plug or Something Else?
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 Which System Is better?: Watchman or Cardiac Plug or Something Else? Horst Sievert, Annkathrin Brauth, Isabel Schulmeyer, Patrick Boehm, Jonas
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More information